GlassScriptPhysician profile
John M Pulcini
NPI 1447285374
$2,146.75
in general payments reported to CMS, 2019-2025
26 companies · $563 in 2025
The $563 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $236 · 2020: $64.61 · 2021: $170 · 2022: $428 · 2023: $377 · 2024: $309 · 2025: $563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,248.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $228.21 | 2019-2025 | Hizentra, Andembry |
| Glaxosmithkline, LLC. | $204.16 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Pfizer INC. | $181.58 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $173.91 | 2019-2025 | Tezspire, Breztri, Airsupra |
| Biocryst US Sales Co., LLC | $165.81 | 2021-2025 | Orladeyo |
| Genzyme Corporation | $164.31 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $148.13 | 2021-2025 | Takhzyro, Cuvitru |
| Amgen INC. | $108.57 | 2022-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $81.95 | 2025 | |
| Pharming Healthcare, INC. | $77.22 | 2020-2025 | Ruconest |
| Kaleo, INC. | $75.16 | 2019-2024 | Auvi-Q |
| Genentech USA, INC. | $68.31 | 2019-2025 | Xolair |
| Incyte Corporation | $65.21 | 2021-2025 | Opzelura |
| Grifols USA, LLC | $55.51 | 2021-2025 | Xembify |
| Hospira, INC. | $49.44 | 2020-2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $45.38 | 2024-2025 | Ebglyss |
| Alk-Abello, INC | $40.13 | 2019-2023 | Grastek, Odactra, Ragwitek |
| Hikma Pharmaceuticals USA | $36.12 | 2022-2023 | Ryaltris |
| Ars Pharmaceuticals Operations, INC. | $30.02 | 2025 | Neffy |
| Greer Laboratories, INC. | $29.26 | 2025 | Oralair |
| Jubilant Hollisterstier LLC | $22.25 | 2025 | |
| Gc Biopharma USA, INC. | $22.07 | 2024 | Alyglo |
| Abbvie INC. | $21.85 | 2023 | |
| Optinose US, INC. | $21.85 | 2021 | |
| Shire North American Group INC | $18.07 | 2019 | |
| Vyaire Medical, INC. | $12.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Pulcini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.